JUL 08, 2017 3:00 PM PDT

Cooling Cap Device Scores Another Big Nod from FDA

WRITTEN BY: Xuan Pham

The cooling cap device that limits hair loss during chemotherapy just scored another thumbs up from the FDA. The regulatory body recently approved the expanded use of the cap for patients with solid cancers.

Dignicap \\ Image credit: Dignitana

“We are pleased to expand the use of this product for cancer patients with solid tumors to potentially minimize chemotherapy-induced hair loss,” said Dr. Binita Ashar, director, Division of Surgical Devices, in the FDA’s Center for Devices and Radiological Health. “Managing the side effects of chemotherapy is a critical component to overall health and quality of life.”

Traditional cancer treatment with chemotherapy involves using highly toxic drugs to kill errant cancer cells. Because the majority of these drugs do not discriminate between cancer and normal cells, patients experience collateral damages as adverse side effects. Hair loss (alopecia) is a common side effect of certain types of chemotherapy, typically associated with treatment for breast cancer. Though considered a temporary effect, minimizing hair loss is important to the quality of life for many patients.

Named DigniCap, the cooling system is manufactured by Dignitana in Sweden. It works by circulating a liquid coolant to a tight-fitting silicone cap worn on the head during chemotherapy sessions. A second cap made of neoprene covers this cooling cap to act as insulation and prevent loss of cooling. The entire system is computerized with sensors that continuously monitor scalp temperature and allow the system to maintain optimal cooling throughout treatment.

The coldness of the cap acts to constrict blood vessels in the scalp, reducing blood flow to the hair follicles and protecting the hair from the flow of toxic chemotherapy agents in the body. In addition, the cooling action slows down cell division activities of the hair follicles, which makes them less susceptible to the uptake of chemotherapy drugs. These factors together reduce the risk of hair loss associated with cancer treatment.

In 2015, the device was originally approved for breast cancer patients following the results of a study that showed the Dignicap minimized hair loss in 66 percent of breast cancer patients undergoing chemotherapy.

Of note, not all patients with solid cancers will qualify for the Dignicap. For example, the cap isn’t suitable for pediatric patients, those with cold sensitivities, or those with contraindicated cancers or treatments.

Nevertheless, the expanded access will help a larger group of patients by minimizing the psychological impact of the diagnosis and making the chemotherapy process more tolerable. Reducing hair loss during chemotherapy allows more patients to retain some normalcy and privacy in their lives.

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 18, 2021
Technology
Tracking System Maps How Cancer Cells Evolve, Providing New Treatment Insights
AUG 18, 2021
Tracking System Maps How Cancer Cells Evolve, Providing New Treatment Insights
All cells in a tumor share some genetic similarities, but also have key differences, often hindering effective treatment ...
AUG 18, 2021
Cannabis Sciences
Cancer Patients Use Less Cannabis than General Public
AUG 18, 2021
Cancer Patients Use Less Cannabis than General Public
Despite increasing legalization for recreational cannabis across the US, cancer patients have largely abstained from usi ...
SEP 02, 2021
Immunology
Hobit Activates Cancer-Killing Immune Cells
SEP 02, 2021
Hobit Activates Cancer-Killing Immune Cells
Innate lymphoid cells, or ILCs, are specialized immune cells that are increasingly entering the research spotlight. Thes ...
OCT 18, 2021
Cancer
The History of Immunotherapy: Toxins, Targets & T Cells
OCT 18, 2021
The History of Immunotherapy: Toxins, Targets & T Cells
Cancer immunotherapy, a treatment that directly enhances a patient’s immune system, is typically perceived as a mo ...
NOV 08, 2021
Cancer
Genetic Explanation for Low Cancer Incidence in Elephants
NOV 08, 2021
Genetic Explanation for Low Cancer Incidence in Elephants
Elephants possess two qualities that might make one expect they are at high risk of developing cancer; they are large an ...
NOV 15, 2021
Cancer
Dogs Get Cancer Too
NOV 15, 2021
Dogs Get Cancer Too
“Cancer” isn’t a word anyone wants to hear from their doctor. However, many dog owners may not conside ...
Loading Comments...